Liver Mass Found in 38-Year-Old Woman

Poll

A 38-year-old woman presents with a liver mass. After further evaluation a biopsy is performed. What is your diagnosis?

A 38-year-old woman presents with a liver mass. Looking at the pathology slide below, what is your diagnosis?

What is your diagnosis?

A. Epithelioid hemangioendothelioma
B. Hepatocellular carcinoma
C. Hemangioma
D. Cirrhosis
Recent Videos
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Vinay K. Puduvalli, MD, is featured in this series.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Related Content
The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.

Venetoclax/Cladribine Improves Response Rates in AML/MDS Cohorts

Ariana Pelosci
December 9th 2024
Article

The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Andrew M. Evens, DO, MBA, MSc
December 9th 2024
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome.

Venetoclax Plus Hypomethylating Agents Elicit Encouraging Responses in MDS

Roman Fabbricatore
December 9th 2024
Article

Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Navtemadlin shows influence in myelofibrosis hallmarks such as CD34-positive cell proliferation and pro-inflammatory cytokines in the phase 3 BOREAS trial.

Novel MDM2 Inhibitor Shows Disease-Modifying Activity in R/R Myelofibrosis

Morgan Bayer
December 9th 2024
Article

Navtemadlin shows influence in myelofibrosis hallmarks such as CD34-positive cell proliferation and pro-inflammatory cytokines in the phase 3 BOREAS trial.

Low Dose Deferasirox Yields Promising Transfusion Independence in MDS

Low Dose Deferasirox Yields Promising Transfusion Independence in MDS

Tim Cortese
December 9th 2024
Article

For patients with MDS who are relapsed/refractory to erythropoietin stimulating agents, low-dose deferasirox demonstrated promising efficacy and tolerability outcomes.